| MicroRNA signatures in tissues and plasma predict development and prognosis of computed tomography detected lung cancer M Boeri, C Verri, D Conte, L Roz, P Modena, F Facchinetti, E Calabrò, ... Proceedings of the National Academy of Sciences 108 (9), 3713-3718, 2011 | 821 | 2011 |
| Clinical utility of a plasma-based miRNA signature classifier within computed tomography lung cancer screening: a correlative MILD trial study G Sozzi, M Boeri, M Rossi, C Verri, P Suatoni, F Bravi, L Roz, D Conte, ... Journal of clinical oncology 32 (8), 768, 2014 | 459 | 2014 |
| Biomarkers in lung cancer screening: achievements, promises, and challenges LM Seijo, N Peled, D Ajona, M Boeri, JK Field, G Sozzi, R Pio, JJ Zulueta, ... Journal of Thoracic Oncology 14 (3), 343-357, 2019 | 405 | 2019 |
| Antibody–Fc/FcR interaction on macrophages as a mechanism for hyperprogressive disease in non–small cell lung cancer subsequent to PD-1/PD-L1 blockade G Lo Russo, M Moro, M Sommariva, V Cancila, M Boeri, G Centonze, ... Clinical Cancer Research 25 (3), 989-999, 2019 | 385 | 2019 |
| Role of microRNAs in lung cancer: microRNA signatures in cancer prognosis M Boeri, U Pastorino, G Sozzi The Cancer Journal 18 (3), 268-274, 2012 | 111 | 2012 |
| Mir-660 is downregulated in lung cancer patients and its replacement inhibits lung tumorigenesis by targeting MDM2-p53 interaction O Fortunato, M Boeri, M Moro, C Verri, M Mensah, D Conte, L Caleca, ... Cell death & disease 5 (12), e1564-e1564, 2014 | 94 | 2014 |
| Assessment of circulating microRNAs in plasma of lung cancer patients O Fortunato, M Boeri, C Verri, D Conte, M Mensah, P Suatoni, U Pastorino, ... Molecules 19 (3), 3038-3054, 2014 | 80 | 2014 |
| Potential biomarkers for lung cancer screening G Sozzi, M Boeri Translational lung cancer research 3 (3), 139, 2014 | 79 | 2014 |
| YAP1 acts as oncogenic target of 11q22 amplification in multiple cancer subtypes E Lorenzetto, M Brenca, M Boeri, C Verri, E Piccinin, P Gasparini, ... Oncotarget 5 (9), 2608, 2014 | 79 | 2014 |
| Circulating miRNAs and PD-L1 tumor expression are associated with survival in advanced NSCLC patients treated with immunotherapy: a prospective study M Boeri, M Milione, C Proto, D Signorelli, G Lo Russo, C Galeone, C Verri, ... Clinical Cancer Research 25 (7), 2166-2173, 2019 | 78 | 2019 |
| Circulating microRNA signature as liquid-biopsy to monitor lung cancer in low-dose computed tomography screening S Sestini, M Boeri, A Marchiano, G Pelosi, C Galeone, C Verri, P Suatoni, ... Oncotarget 6 (32), 32868, 2015 | 78 | 2015 |
| Circulating mir‐320a promotes immunosuppressive macrophages M2 phenotype associated with lung cancer risk O Fortunato, C Borzi, M Milione, G Centonze, D Conte, M Boeri, C Verri, ... International journal of cancer 144 (11), 2746-2761, 2019 | 65 | 2019 |
| Stopping smoking reduces mortality in low-dose computed tomography screening participants U Pastorino, R Boffi, A Marchianò, S Sestini, E Munarini, G Calareso, ... Journal of Thoracic Oncology 11 (5), 693-699, 2016 | 61 | 2016 |
| Therapeutic use of microRNAs in lung cancer O Fortunato, M Boeri, C Verri, M Moro, G Sozzi BioMed research international 2014, 2014 | 60 | 2014 |
| Prognostic determinants in epithelioid sarcoma P Gasparini, F Facchinetti, M Boeri, E Lorenzetto, A Livio, A Gronchi, ... European Journal of Cancer 47 (2), 287-295, 2011 | 53 | 2011 |
| Baseline and postoperative C-reactive protein levels predict mortality in operable lung cancer U Pastorino, D Morelli, G Leuzzi, M Gisabella, P Suatoni, F Taverna, ... European journal of cancer 79, 90-97, 2017 | 42 | 2017 |
| Establishment of patient derived xenografts as functional testing of lung cancer aggressiveness M Moro, G Bertolini, R Caserini, C Borzi, M Boeri, A Fabbri, G Leone, ... Scientific Reports 7 (1), 6689, 2017 | 41 | 2017 |
| MicroRNA based liquid biopsy: the experience of the plasma miRNA signature classifier (MSC) for lung cancer screening M Mensah, C Borzi, C Verri, P Suatoni, D Conte, U Pastorino, F Orazio, ... JoVE (Journal of Visualized Experiments), e56326, 2017 | 38 | 2017 |
| Recent advances of microRNA-based molecular diagnostics to reduce false-positive lung cancer imaging M Boeri, S Sestini, O Fortunato, C Verri, P Suatoni, U Pastorino, G Sozzi Expert review of molecular diagnostics 15 (6), 801-813, 2015 | 38 | 2015 |
| DRAGO (KIAA0247), a new DNA damage–responsive, p53-inducible gene that cooperates with p53 as oncosuppressor F Polato, P Rusconi, S Zangrossi, F Morelli, M Boeri, A Musi, S Marchini, ... Journal of the National Cancer Institute 106 (4), dju053, 2014 | 19 | 2014 |
